Specialty pharmaceutical industry 2011 yearbook
Download
1 / 6

specialty pharmaceutical industry - 2011 yearbook - PowerPoint PPT Presentation


  • 304 Views
  • Uploaded on

HIV/AIDS and Rheumatoid Arthritis are the Major Indications, Which Will Drive the Specialty Pharmaceutical Market in the Future

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'specialty pharmaceutical industry - 2011 yearbook' - rgunnam


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Slide2 l.jpg

HIV/AIDS and Rheumatoid Arthritis are the Major Indications, Which Will

Drive the Specialty Pharmaceutical Market in the Future

The Specialty pharmaceutical market is dominated by rheumatoid arthritis and HIV/AIDS in the year 2009. Rheumatoid arthritis accounted for 26% of the total market, while HIV/AIDS closely followed it with a market share of 25%. Alzheimer’s disease, Attention Deficit Hyperactive Disorder (ADHD) and epilepsy have also shown strong market presence, holding shares of 14%, 8% and 7% respectively in 2009.

The global HIV/AIDS market has witnessed a strong growth over the past few years. According to GBI Research analysis, the market is estimated to grow at a steady rate of 3% between 2009 and 2017. Increased disease awareness levels have increased treatment seeking and diagnosed

populations in the US, Europe and Japan. Furthermore the progress in HIV treatment and introduction of Highly Active Antiretroviral Therapy (HAART) and other effective drugs have contributed effectively to the market growth.

On the other hand the global rheumatoid arthritis market also has recorded a strong growth over the past few years. GBI Research forecasts the market to grow at a better compound annual growth rate (CAGR) of 8.6% between 2009 and 2017. The major drivers for the growth of the rheumatoid arthritis therapeutics market are the increase in the incidence rate and prevalence rate. The introduction of


Slide3 l.jpg

state-of-the-art diagnostic tools to detect rheumatoid arthritis at an early stage is another factor that will be driving the growth of this market.

In addition age related macular degeneration market has grown historically at high growth rate and it is expected to grow at approximately 10% between 2009 and 2017. Increasing diseased population and diagnosis rates are the major drivers of the market growth.

Strong Product Pipeline will Drive the Specialty Pharmaceutical Market

The specialty pharmaceutical market pipeline for the eight conditions has 2,800 molecules in the collective pipeline. The pipeline is active with many new promising molecules and it is dominated by colorectal cancer, followed by Glaucoma and Alzheimer’s disease.

The pipeline consists of the many novel promising molecules that are expected to support the drug in future for many of the indications. The small and niche markets such as the Glaucoma and Alzheimer’s disease have recently been in focus for many pharmaceutical companies.

For further details, please click or add the below link to your browser:

http://gbiresearch.com/Report.aspx?ID=Specialty-Pharmaceutical-Industry-2011-Yearbook&Title=Pharmac&ReportType=Industry_Report


Slide4 l.jpg

Strategic Consolidations Have Led to the Entry of New Players in the

Specialty Pharmaceutical Market

In the past five to six years many pharmaceutical companies have improved their product profiles with respect to the specialty pharmaceutical market. This is due to strategic deals with the aim of introducing new products with better efficacy and safety profiles into the market. Many pharmaceutical companies have acquired or signed licensing and co-development deals with companies possessing potential products for different indications in the Specialty pharmaceutical segment. The acquisition of Wyeth Pharmaceuticals by Pfizer, and the acquisition of ID Biomedical

by GlaxoSmithKline were the major acquisitions in the Specialty pharmaceutical market. Under licensing agreements one of the important deals was a licensing agreement between DiaGenic and Pfizer to develop a biomarker for early stages of Alzheimer’s disease. In addition, Trimeris and F.Hoffmann-La-Roche have entered into a licensing agreement with Novartis to sell Novartis’s branded drug Fuzeon. In addition to these, a large number of co-development deals took place with respect to HIV/AIDS and Alzheimer’s disease therapeutics in the past five to six years.

These strategic consolidations will help the acquirer and licensee companies to diversify their profiles by entering and expanding their presence in the Specialty pharmaceutical market, which will in turn make the market more competitive. These consolidations will also help the companies to generate revenues, thereby increasing the total revenue of the global Specialty pharmaceutical market.


Slide5 l.jpg

Decline in the Alzheimer’s Disease Therapeutics Market Could Restrict the

Growth of Specialty Pharmaceutical Market

The decline in the Alzheimer’s disease market, which is the third largest market in the Specialty pharmaceutical segment, will affect the growth of specialty pharmaceutical market in the future. GBI Research analysis shows that the global Alzheimer’s disease (AD) therapeutics market is expected to decline at a CAGR of 3% by the year 2017. The market structure is projected to change in the near future following the patent expiry of the leading drugs in the next two to three years. The next couple of years will witness major products going off-patent leading to a flood of

generics into the market. Aricept, the most popular drug in this market will lose its patent protection in 2010, which will affect the entire market. The flood of generics will lead to a price decline which will restrict market growth.

GBI Research, the leading business intelligence provider has released its latest research “Specialty Pharmaceutical Industry - 2011 Yearbook”, which essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), colorectal cancer, epilepsy, glaucoma, Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), macular degeneration and rheumatoid arthritis, including their annual cost of therapy (ACT) and revenue. In addition, the geographical distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes


Slide6 l.jpg

insights into the specialty pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:

http://gbiresearch.com/Report.aspx?ID=Specialty-Pharmaceutical-Industry-2011-Yearbook&Title=Pharmac&ReportType=Industry_Report

Visit our report store: http://www.gbiresearch.com

For more details contact:

[email protected]

North America: +1 646 395 5477

Europe: +44 207 753 4299

+44 1204 543 533

Asia Pacific: +91 40 6616 6782


ad